Addressing age-related decline in immunity.
SHINGRIX – specifically formulated to help address age-related decline in varicella zoster virus specific immunity in adults 50 years of age and older.1,4,5
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
Anoro Ellipta 20 mcg
has been added to your basket
SHINGRIX has a clinically acceptable safety and tolerability profile.1-3
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
Date of preparation: March 2022 PM-IE-SGX-WCNT-210005